drug_type
RELEVANT_DRUG
intervention_type
Biologic (monoclonal antibody; immune checkpoint inhibitor)
drug_description
An anti-CTLA-4 monoclonal antibody (marketed as Yervoy) that enhances T-cell activation by blocking CTLA-4 binding to CD80/CD86; may reduce intratumoral Tregs via Fc-mediated effector functions.
nci_thesaurus_concept_id
C2654
nci_thesaurus_preferred_term
Ipilimumab
nci_thesaurus_definition
A recombinant human immunoglobulin (Ig) G1 monoclonal antibody directed against the human T-cell receptor cytotoxic T-lymphocyte-associated antigen 4 (CTLA4), with immune checkpoint inhibitory and antineoplastic activities. Ipilimumab binds to CTLA4 expressed on T-cells and inhibits the CTLA4-mediated downregulation of T-cell activation. This leads to a cytotoxic T-lymphocyte (CTL)-mediated immune response against cancer cells. CTLA4, an inhibitory receptor and member of the immunoglobulin superfamily, plays a key role in the downregulation of the immune system.
drug_mesh_term
Ipilimumab
drug_category
INHIBITORY ANTIBODY
drug_class
Inhibitor
drug_delivery_route
Intravenous
drug_mechanism_of_action
Anti-CTLA-4 monoclonal antibody (checkpoint inhibitor) that blocks CTLA-4 interaction with CD80/CD86 on antigen-presenting cells, relieving inhibitory signaling and enhancing CD28-mediated T‑cell activation; its IgG1 Fc may deplete intratumoral regulatory T cells via effector functions, promoting antitumor cytotoxic T‑cell responses.
drug_name
Ipilimumab
nct_id_drug_ref
NCT06159101